Mulay James sold $1.8M of CGON
Mulay James sold 24,165 shares of CG Oncology, Inc. (CGON) at $75.16 ($1.82M total) on 2026-07-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale size, price ($75.1600/share), and post-transaction holdings (0 shares) under a pre-arranged 10b5-1 plan.
Market read
Traders may note insider selling, but the 10b5-1 structure and lack of fundamental updates make it low-signal for valuation.
What to watch
The filing shows the director ends with 0 shares, but it does not reveal whether future sales are planned, nor does it include any concurrent corporate event.
Background
The article is an SEC Form 4 insider transaction disclosure for CG Oncology, Inc., reported by director Mulay James.
Ticker impact
Director Mulay James filed a Form 4 showing an open-market sale of 24,165 CG Oncology shares for about $1.82M, leaving 0 shares.
Likely limited near-term impact; any effect would be sentiment-only and typically fades unless accompanied by other disclosures.
The filing is an insider transaction (S sale) with a stated pre-arranged 10b5-1 plan and no new company fundamentals, guidance, or events.
Market effects
Minimal; insider sales do not provide sector-level datapoints without accompanying company-specific catalysts.
None indicated.
None indicated.
Counterpoint
A 10b5-1 sale can be purely mechanical and may not signal reduced confidence; the director could have needed liquidity unrelated to fundamentals.
Key entities
- issuerCG Oncology, Inc.
Company whose director insider sale is disclosed on Form 4.
- insiderMulay James
Director who sold 24,165 shares in an open-market transaction under a 10b5-1 plan.